Chugai takes full advantage of its proprietary technology strengths and global network to continuously create innovative drugs from its own research. Our new drug development activities are balanced between antibodies and small-molecule medicines. Moreover, to maximize the value of our proprietary technologies, we further refine and apply them to other target molecules. By repeating the cycle of “developing original technologies to address unmet medical need”, followed by “developing innovative therapies” and “applying these technologies in drug discovery research”, we can continuously generate new first-in-class*1 and best-in-class*2 drugs.
|*1||An original drug that is highly novel and useful, and will significantly change the therapeutic system|
|*2||A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target|
Chugai’s Innovative Antibody Technologies
Chugai has been developing new technologies to address unmet medical need. By making groundbreaking advances in research technology, we have developed a succession of technologies that overturned conventional wisdom about antibody engineering technologies. Examples include our development of the Recycling Antibody®, Sweeping Antibody® and bispecific antibody technologies.
In addition, we have selected drug discovery technologies for middle molecules as a candidate for our next generation core technology in addition to antibody engineering and small-molecule technologies, and will make concentrated investments to establish this new candidate and quickly generate projects.
Mechanisms of antibody therapeutics and an introduction to Chugai’s next-generation antibody engineering technologies